Avanamd Healthcare
What Is PK/PD Analysis?
Pharmacokinetic (PK) and Pharmacodynamic (PD) analyses help researchers understand how a medicine moves through the body and how it produces its effects. Pharmacokinetics examines what the body does to a drug, including its absorption, distribution, metabolism, and elimination (ADME). Pharmacodynamics focuses on the relationship between drug exposure, dosage, and the resulting pharmacological or toxicological effects.
PK analysis helps drug developers understand the relationship between administered doses and drug concentrations in blood or plasma across different patient populations. It can also help evaluate whether dose adjustments may be necessary for specific demographic groups, patients with impaired drug elimination, or populations with particular clinical needs. These analyses contribute to understanding drug exposure, supporting dose selection, and evaluating appropriate dosing strategies during clinical development.
Avanamd Healthcare supports PK analysis through data review, statistical analysis, and reporting activities aligned with study requirements. Depending on the project scope, pharmacokinetic analysis can be conducted as a standalone service or alongside biostatistics and statistical programming. Bioanalytical data received from laboratories can be processed and analyzed using appropriate PK software and analytical methods to derive relevant pharmacokinetic parameters.
Pharmacodynamic (PD) analysis evaluates the relationship between drug dose or exposure and the resulting biological, pharmacological, or toxicological response. These analyses can help researchers understand treatment effects, dose-response relationships, and the influence of relevant factors on patient responses. In some cases, receptor interactions and competing drugs may influence the observed pharmacodynamic response.
Pharmacokinetic & Pharmacodynamic Services
Understanding the pharmacokinetic profile of an investigational medicine is an important part of clinical development. Differences in drug absorption, distribution, metabolism, and elimination can influence exposure, treatment response, and safety. Appropriate PK and PD analyses help researchers evaluate these relationships and support evidence-based decisions throughout drug development.
Avanamd Healthcare supports pharmacokinetic, pharmacodynamic, and integrated PK/PD analysis through statistical expertise, analytical methods, and structured reporting tailored to clinical study objectives.
Study Design Support
Input into study design, sample size estimation, and optimization of pharmacokinetic sampling schedules.
Non-Compartmental PK Analysis
Calculation and interpretation of relevant pharmacokinetic parameters using appropriate analytical methods.
Interim PK Analysis
Timely interim pharmacokinetic analyses, including early-phase and first-in-human studies.
Clinical Study Report Support
Preparation and interpretation of PK/PD results for inclusion in Clinical Study Reports (CSRs).
Compartmental PK Modeling
Modeling approaches to characterize drug concentration-time profiles.
Statistical PK Analysis
Bioequivalence, bioavailability, food-effect, drug-drug interaction, dose-proportionality, and special-population analyses.
PK Handover Documentation
Documentation of analytical methods, parameters, and findings for subsequent review.
Pharmacodynamic Analysis
Evaluation of drug-related responses using appropriate graphical and statistical approaches.
PK/PD Modeling
Linear and nonlinear mixed-effects modeling to investigate drug exposure-response relationships.
Simulation and Dose Evaluation
Modeling and simulation to explore systemic exposure and potential pharmacodynamic effects under alternative dosing regimens.
Supporting Informed Drug Development Decisions
Avanamd Healthcare combines pharmacokinetic and pharmacodynamic analytical support to help research teams understand drug exposure, evaluate treatment responses, and investigate dose-response relationships. Through appropriate statistical methods, modeling, simulation, and reporting, we aim to support dose selection, study interpretation, and informed clinical development decisions.